FOLH1 and metastatic neoplasm: Our objectives were (i) to assess the prevalence of metastatic PCa in patients with biochemical failure following RP and PSA levels ≤ 1 ng/mL, as detected by <sup>18</sup>F-PSMA-1007 PET/CT (PSMA-PET), and (ii) to identify predictors of metastatic disease.<h4>Methods</h4>Fifty-five patients with biochemical recurrence (BCR, n = 47) or persistent disease (n = 8) following RP as their primary and only prior treatment were retrospectively included if presenting with PSA levels ≤ 1 ng/mL.